Compare Ginkgo Bioworks Holdings Inc (DNA) vs FedEx Corporation (FDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs FedEx Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13.18 (market cap $763.64M), while FedEx Corporation trades at $291.66 (market cap $69.04B). The key difference: FedEx Corporation is far larger — about 90.4× Ginkgo Bioworks Holdings Inc's market cap, and FedEx Corporation pays a 1.67% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and FedEx Corporation for 87 Days on average.
| DNA | FDX | |
|---|---|---|
Market Cap | $763.64M | $69.04B |
Volume | 3,204,177 | 1,287,367 |
Sector | Health | Industrials |
52-Week High | $15.83 | $339.35 |
52-Week Low | $5.48 | $180.87 |
Typical Hold Time | 7 Days | 87 Days |
Enterprise Value | $865.59M | $98.68B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.
Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.
FDX trades at $290.98, up 0.67% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $6.31 exceeding the $5.96 estimate. Revenue for 2025 was $87.93 billion, with a net income margin of 4.68%. Recent news includes a $300 million order for electric trucks from Harbinger and shareholder approval of executive compensation.
The outlook is mixed: analyst consensus is bullish with a $307.55 price target, but rising fuel costs and geopolitical tensions pose near-term risks. Earnings growth and cost-cutting initiatives support upside, while margin pressure from higher diesel prices and competitive pressures are key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
